LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

Eli Lilly’s Q1 earnings smashed expectations, fueled by surging demand for its blockbuster drugs Zepbound and Mounjaro. The ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...

Eli Lilly’s LLY first-quarter revenue grew 45%, as combined sales for Mounjaro (diabetes) and Zepbound (obesity) rose ...

As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S. | Eli Lilly CEO Dave Ricks is joining a growing number of pharma chiefs calling for tax ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its [tariff rollout]( ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy ...

Eli Lilly stock has been a big-time winner ... retaliatory tariffs from other countries could also weigh on Lilly's business; the company could start to see diminished brand equity in ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low volatility stocks to buy now. The US stock market experienced a turbulent first ...

But what matters more than Lilly's accomplishments in the past is what the company could do in the future. Where will Eli Lilly be in five years? Where to invest $1,000 right now? Our analyst team ...

Indianapolis-based Eli Lilly and Co. plans to manufacture its new weight-loss pill—if it’s approved—in the United States for patients around the world as President Donald Trump presses ...